Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Morgan Stanley raises gold target price to $3,800, silver may see better-than-expected performance

Morgan Stanley raises gold target price to $3,800, silver may see better-than-expected performance

智通财经智通财经2025/09/02 05:03
Show original
By:智通财经

According to Jinse Finance APP, the latest research report from Morgan Stanley points out that the precious metals market is entering an upward cycle driven by multiple favorable factors, with gold and silver prices expected to diverge amid the Federal Reserve's rate-cutting cycle and changes in the macro environment. According to the report, historical data shows that precious metals usually experience significant gains after the Federal Reserve cuts rates—gold rises by an average of 6% (up to 14%) within 60 days after a rate cut, while silver rises by an average of 4% during the same period. This pattern provides important reference for the current market.

Morgan Stanley raises gold target price to $3,800, silver may see better-than-expected performance image 0

Figure 1

On the demand side, global gold ETFs have increased their holdings by about 440 tons this year, reversing the net outflow trend of the previous four years, indicating a rebound in institutional demand for gold allocation. Silver ETF holdings have increased by 127 million ounces during the same period, but the report warns that speculative trading may lead to excessive price surges.

Morgan Stanley raises gold target price to $3,800, silver may see better-than-expected performance image 1

Figure 2

It is worth noting that India's gold import data for July has shown signs of improvement. Although jewelry demand in the second quarter hit its lowest level since Q3 2020, expectations of increased consumer purchasing power brought by local Goods and Services Tax (GST) reforms may lay the groundwork for a subsequent demand recovery.

In terms of price forecasts, Morgan Stanley has set its year-end target price for gold at $3,800 per ounce, with three core driving factors: the continued progress of the Federal Reserve's rate-cutting cycle, the potential further weakening of the US Dollar Index (DXY), and the potential recovery of jewelry consumption in emerging markets.

For silver, although analysts remain cautious (target price $40.9 per ounce), the contradiction between stable solar panel production and a 7% year-on-year contraction in Mexican mine supply suggests that silver prices may have upside potential beyond expectations.

Morgan Stanley raises gold target price to $3,800, silver may see better-than-expected performance image 2

Figure 3

The report particularly emphasizes that the strong negative correlation between gold and the US dollar remains a key pricing logic. If the current depreciation trend of the US Dollar Index continues, it will directly benefit precious metals priced in US dollars.

Morgan Stanley raises gold target price to $3,800, silver may see better-than-expected performance image 3

Figure 4

However, the report also highlights risks: although India's GST reform does not directly benefit gold and silver, tax reductions in other areas may indirectly boost consumer purchasing power. In addition, Morgan Stanley's business dealings with related companies should also be considered by investors when making decisions.

Overall, the report believes that gold's safe-haven and anti-inflation attributes during the rate-cutting cycle will support its price increase, while silver needs to find a balance between industrial demand and speculative sentiment. Investors should closely monitor Federal Reserve policy moves, the US dollar trend, and signals of consumption recovery in the Indian market to seize structural opportunities in the precious metals market.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify

In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.

华尔街见闻•2026/11/06 15:01

AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

华尔街见闻•2026/11/06 13:42
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight

Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.

华尔街见闻•2026/11/06 13:23